Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

JPMorgan said Eli Lilly is enrolling about 500,000 new obesity drug patients per month, and maintains more than 60% share in ...

Here's how Eli Lilly compares to Johnson & Johnson and Becton, Dickinson, a couple of top healthcare stocks with dividend growth streaks of more than 50 years.

Key Points About This Article: Eli Lilly remains a top big pharma stock investors are flocking to in this time of uncertainty, due to the company’s strong growth profile.

Given Lilly's current revenue from its GLP-1 treatments, the potential size of the market suggests that much more growth could be in store.

Eli Lilly's sales and profit growth has been impressive Eli Lilly has a solid roster of products in its portfolio already, with Mounjaro and Zepbound leading the charge.

Eli Lilly didn't generate much growth last year, but its future looks promising. Mounjaro has the potential to be a game-changing product for the business. It could significantly propel the ...

Eli Lilly also has a healthy pipeline outside of obesity and the potential near-term launches of lebrikizumab and donanemab could positively impact its near- and long-term growth trajectory.

Eli Lilly's growth has been accelerating -- and that could continue For years, Eli Lilly has been generating solid growth numbers -- but lately, they've been accelerating rapidly.

Eli Lilly (NYSE: LLY) may seem like an expensive stock to invest in right now. Its $720 billion market capitalization also means it's the most valuable healthcare stock in the world. It's one that ...